Oncolytic adenovirus (OAd) therapy is one of the effective treatment strategies for solid malignant tumors, and E1A is a requirement for adenovirus replication. Thus, it is very important to study how E1A regulates adenovirus replication. The p300 and E1A expression were detected by Western blot. The viral replication of OAd was detected by virus replication assay. The interaction between E1A and p300 was analyzed by immunofluorescence and immunoprecipitation assays. The therapeutic effect of OAd-shp300 was analyzed by MTT assay and animal experiments. The results indicated that OAd infection or E1A overexpression could reduce p300 expression, implying that OAd might reduce p300 expression via E1A, and p300 knockdown could enhance viral replication and cell cytotoxicity of OAd. Furthermore, E1A promoted viral replication of OAd via mediating p300 ubiquitination degradation to inhibit the IFI16/STING/IRF3/IFN-β signaling pathway. Additionally, OAd-shp300 induced highly efficient viral replication and potent antitumor activity both in vitro and in vivo. In this study, OAd can reduce p300 expression by promoting its ubiquitination via E1A, thereby enhancing viral replication and cell cytotoxicity. Therefore, this study can provide a biomarker for screening patients who are sensitive to OAd and new ideas for clinical tumor treatment.
| [1] |
J. Fueyo, C. Gomez-Manzano, R. Alemany, et al., “A Mutant Oncolytic Adenovirus Targeting the Rb Pathway Produces Anti-Glioma Effect In Vivo,” Oncogene 19, no. 1 (2000): 2–12.
|
| [2] |
W. Zhu, L. Wei, H. Zhang, J. Chen, and X. Qin, “Oncolytic Adenovirus Armed With IL-24 Inhibits the Growth of Breast Cancer In Vitro and In Vivo,” Journal of Experimental & Clinical Cancer Research 31, no. 1 (2012): 51.
|
| [3] |
C. Ying, B. D. Xiao, Y. Qin, et al., “GOLPH2-Regulated Oncolytic Adenovirus, GD55, Exerts Strong Killing Effect on Human Prostate Cancer Stem-Like Cells In Vitro and In Vivo,” Acta Pharmacologica Sinica 39, no. 3 (2018): 405–414.
|
| [4] |
M. Anwar, M. L. Arendt, M. Ramachandran, et al., “Ixovex-1, a Novel Oncolytic E1B-Mutated Adenovirus,” Cancer Gene Therapy 29, no. 11 (2022): 1628–1635.
|
| [5] |
S. Lee, W. Yang, D. K. Kim, et al., “Inhibition of MEK-ERK Pathway Enhances Oncolytic Vaccinia Virus Replication in Doxorubicin-Resistant Ovarian Cancer,” Molecular Therapy-Oncolytics 25 (2022): 211–224.
|
| [6] |
L. Deng, X. Yang, J. Fan, et al., “An Oncolytic Vaccinia Virus Armed With GM-CSF and IL-24 Double Genes for Cancer Targeted Therapy,” OncoTargets and Therapy 13 (2020): 3535–3544.
|
| [7] |
N. Aldrak, S. Alsaab, A. Algethami, et al., “Oncolytic Herpes Simplex Virus-Based Therapies for Cancer,” Cells 10, no. 6 (2021): 1541.
|
| [8] |
B. Hong, U. Sahu, M. P. Mullarkey, and B. Kaur, “Replication and Spread of Oncolytic Herpes Simplex Virus in Solid Tumors,” Viruses 14, no. 1 (2022): 118.
|
| [9] |
S. Mulvihill, R. Warren, A. Venook, et al., “Safety and Feasibility of Injection With an E1B-55 kDa Gene-Deleted, Replication-Selective Adenovirus (ONYX-015) Into Primary Carcinomas of the Pancreas: A Phase I Trial,” Gene Therapy 8, no. 4 (2001): 308–315.
|
| [10] |
Y. S. Chung, M. K. Kim, W. J. Lee, and C. Kang, “Silencing E1A mRNA by RNA Interference Inhibits Adenovirus Replication,” Archives of Virology 152, no. 7 (2007): 1305–1314.
|
| [11] |
R. Ferrari, A. J. Berk, and S. K. Kurdistani, “Viral Manipulation of the Host Epigenome for Oncogenic Transformation,” Nature Reviews Genetics 10, no. 5 (2009): 290–294.
|
| [12] |
R. Ferrari, T. Su, B. Li, et al., “Reorganization of the Host Epigenome by a Viral Oncogene,” Genome Research 22, no. 7 (2012): 1212–1221.
|
| [13] |
S. Radko, M. Koleva, K. M. James, R. Jung, J. S. Mymryk, and P. Pelka, “Adenovirus E1A Targets the DREF Nuclear Factor to Regulate Virus Gene Expression, DNA Replication, and Growth,” Journal of Virology 88, no. 22 (2014): 13469–13481.
|
| [14] |
P. Pelka, J. N. Ablack, G. J. Fonseca, A. F. Yousef, and J. S. Mymryk, “Intrinsic Structural Disorder in Adenovirus E1A: A Viral Molecular Hub Linking Multiple Diverse Processes,” Journal of Virology 82, no. 15 (2008): 7252–7263.
|
| [15] |
P. Pelka, J. N. Ablack, J. Torchia, A. S. Turnell, R. J. Grand, and J. S. Mymryk, “Transcriptional Control by Adenovirus E1A Conserved Region 3 via p300/CBP,” Nucleic Acids Research 37, no. 4 (2009): 1095–1106.
|
| [16] |
R. Ferrari, D. Gou, G. Jawdekar, et al., “Adenovirus Small E1A Employs the Lysine Acetylases p300/CBP and Tumor Suppressor Rb to Repress Select Host Genes and Promote Productive Virus Infection,” Cell Host & Microbe 16, no. 5 (2014): 663–676.
|
| [17] |
J. A. Howe, J. S. Mymryk, C. Egan, P. E. Branton, and S. T. Bayley, “Retinoblastoma Growth Suppressor and a 300-kDa Protein Appear to Regulate Cellular DNA Synthesis,” PNAS 87, no. 15 (1990): 5883–5887.
|
| [18] |
I. Lo Cigno, M. De Andrea, C. Borgogna, et al., “The Nuclear DNA Sensor IFI16 Acts as a Restriction Factor for Human Papillomavirus Replication Through Epigenetic Modifications of the Viral Promoters,” Journal of Virology 89, no. 15 (2015): 7506–7520.
|
| [19] |
J. Dong, L. Kong, S. Wang, et al., “Oncolytic Adenovirus Encoding Apolipoprotein A1 Suppresses Metastasis of Triple-Negative Breast Cancer in Mice,” Journal of Experimental & Clinical Cancer Research 43, no. 1 (2024): 102.
|
| [20] |
D. Wang, C. E. Porter, B. Lim, et al., “Ultralow-Dose Binary Oncolytic/Helper-Dependent Adenovirus Promotes Antitumor Activity in Preclinical and Clinical Studies,” Science Advances 9, no. 13 (2023): eade6790.
|
| [21] |
M. Lu, Z. Xu, F. Wei, et al., “Oncolytic Adenovirus Carrying SPAG9-shRNA Enhanced the Efficacy of Docetaxel for Advanced Prostate Cancer,” Anti-Cancer Drugs 33, no. 2 (2022): 142–148.
|
| [22] |
H. Zhang, Y. Zhang, J. Dong, et al., “Recombinant Oncolytic Adenovirus Expressing a Soluble PVR Elicits Long-Term Antitumor Immune Surveillance,” Molecular Therapy-Oncolytics 20 (2021): 12–22.
|
| [23] |
L. Huang, H. Zhao, M. Shan, et al., “Oncolytic Adenovirus H101 Ameliorate the Efficacy of Anti-PD-1 Monotherapy in Colorectal Cancer,” Cancer Medicine 11, no. 23 (2022): 4575–4587.
|
| [24] |
P. Zhou, X. Wang, M. Xing, et al., “Intratumoral Delivery of a Novel Oncolytic Adenovirus Encoding Human Antibody Against PD-1 Elicits Enhanced Antitumor Efficacy,” Molecular Therapy-Oncolytics 25 (2022): 236–248.
|
| [25] |
S. Shinoda, N. S. Sharma, N. Nakamura, et al., “Interferon-Expressing Oncolytic Adenovirus + Chemoradiation Inhibited Pancreatic Cancer Growth in a Hamster Model,” Cancer Science 114, no. 9 (2023): 3759–3769.
|
| [26] |
D. de la Nava, I. Ausejo-Mauleon, V. Laspidea, et al., “The Oncolytic Adenovirus Delta-24-RGD in Combination With ONC201 Induces a Potent Antitumor Response in Pediatric High-Grade and Diffuse Midline Glioma Models,” Neuro-Oncology 26, no. 8 (2024): 1509–1525.
|
| [27] |
S. M. O'Cathail, T. D. Pokrovska, T. S. Maughan, K. D. Fisher, L. W. Seymour, and M. A. Hawkins, “Combining Oncolytic Adenovirus With Radiation—A Paradigm for the Future of Radiosensitization,” Frontiers in Oncology 7 (2017): 153.
|
| [28] |
H. Gao, X. Zhang, Y. Ding, R. Qiu, Y. Hong, and W. Chen, “Synergistic Suppression Effect on Tumor Growth of Colorectal Cancer by Combining Radiotherapy With a TRAIL-Armed Oncolytic Adenovirus,” Technology in Cancer Research & Treatment 18 (2019): 1533033819853290.
|
| [29] |
Z. J. Xia, J. H. Chang, L. Zhang, et al., “Phase III Randomized Clinical Trial of Intratumoral Injection of E1B Gene-Deleted Adenovirus (H101) Combined With Cisplatin-Based Chemotherapy in Treating Squamous Cell Cancer of Head and Neck or Esophagus,” Ai Zheng = Aizheng 23, no. 12 (2004): 1666–1670.
|
| [30] |
D. Kirn, “Clinical Research Results With dl1520 (Onyx-015), a Replication-Selective Adenovirus for the Treatment of Cancer: What Have We Learned?,” Gene Therapy 8, no. 2 (2001): 89–98.
|
| [31] |
A. A. Stepanenko and V. P. Chekhonin, “Tropism and Transduction of Oncolytic Adenovirus 5 Vectors in Cancer Therapy: Focus on fiber Chimerism and Mosaicism, Hexon and pIX,” Virus Research 257 (2018): 40–51.
|
| [32] |
T. Isobe, C. Uchida, T. Hattori, K. Kitagawa, T. Oda, and M. Kitagawa, “Ubiquitin-Dependent Degradation of Adenovirus E1A Protein Is Inhibited by BS69,” Biochemical and Biophysical Research Communications 339, no. 1 (2006): 367–374.
|
| [33] |
G. R. Gariano, V. Dell'Oste, M. Bronzini, et al., “The Intracellular DNA Sensor IFI16 Gene Acts as Restriction Factor for Human Cytomegalovirus Replication,” PLOS Pathogens 8, no. 1 (2012): e1002498.
|
| [34] |
T. Rothmann, A. Hengstermann, N. J. Whitaker, M. Scheffner, and H. zur Hausen, “Replication of ONYX-015, a Potential Anticancer Adenovirus, Is Independent of p53 Status in Tumor Cells,” Journal of Virology 72, no. 12 (1998): 9470–9478.
|
| [35] |
Q. Chen, B. Yang, X. Liu, X. D. Zhang, L. Zhang, and T. Liu, “Histone Acetyltransferases CBP/p300 in Tumorigenesis and CBP/p300 Inhibitors as Promising Novel Anticancer Agents,” Theranostics 12, no. 11 (2022): 4935–4948.
|
| [36] |
D. Zhang, B. Ma, D. Liu, et al., “Discovery of a Peptide Proteolysis-Targeting Chimera (PROTAC) Drug of p300 for Prostate Cancer Therapy,” EBioMedicine 105 (2024): 105212.
|
| [37] |
C. Heise, A. Sampson-Johannes, A. Williams, F. McCormick, D. D. Von Hoff, and D. H. Kirn, “ONYX-015, an E1B Gene-Attenuated adenovirus, Causes Tumor-Specific Cytolysis and Antitumoral Efficacy That Can be Augmented by Standard Chemotherapeutic Agents,” Nature Medicine 3, no. 6 (1997): 639–645.
|
| [38] |
F. X. Tang, Q. Zheng, Z. H. Huang, Q. G. Zhang, and X. Y. Che, “Construction of Recombinant Adenovirus Using Modified AdEasy System,” Di 1 jun yi da xue xue bao 23, no. 5 (2003): 501–503.
|
| [39] |
R. Zhang, X. Zhang, B. Ma, et al., “Enhanced Antitumor Effect of Combining TRAIL and MnSOD Mediated by CEA-Controlled Oncolytic Adenovirus in Lung Cancer,” Cancer Gene Therapy 23, no. 6 (2016): 168–177.
|
RIGHTS & PERMISSIONS
2026 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.
PDF
(6585KB)
